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Introduction
Haemorrhagic cystitis (HC) is a significant complication after HSCT, the incidence ranging from 2% to 66% according to the type and procedure of HSCT and the age of the patients. HC contributes to post-HSCT morbidity by prolonging hospital stay and severely worsening the quality of life, but its role in increasing post-HSCT mortality is controversial. [1] [2] [3] [4] Several factors contribute to the appearance of HC, which is also reflected in the classification based on the time of onset in the post-HSCT course. Early-onset HC is defined as occurring within ,1 week of HSCT, typically during or within 48 h of conditioning and is considered to result largely from direct toxicity of the conditioning regimen on the urothelial mucosa, particularly from drug metabolites and radiotherapy. Urothelial damage is worsened by inflammation leading to haemorrhagic leakage aggravated by impaired coagulation and thrombocytopenia. Late-onset HC, on the other hand, usually starts around the time of neutrophil engraftment, particularly in the setting of allogeneic HSCT, but can be observed from 2 weeks up to the first 6 months post-HSCT, 1, [5] [6] [7] [8] [9] [10] and is mostly associated with high-level BK polyomavirus (BKPyV) replication. BKPyV is one of 13 known human polyomavirus species. 4, 11 The discovery of BKPyV dates back to 1971 when it was isolated from the urine of the kidney transplant patient B.K., shedding epithelial cells with nuclear viral inclusions, so-called 'decoy cells'. 11, 12 A consistent link of BKPyV to disease was missing until identifying its role in HC after HSCT, 6, 7 and nephropathy after kidney transplantation. [13] [14] [15] We summarize the biology, epidemiology and clinical characteristics of BKPyV-HC in haematology patients and provide recommendations that were discussed and approved at the 6th meeting of the European Conference on Infectious Disease in Leukaemia (ECIL-6) 16 held on 11-12 September 2015 in Sophia Antipolis, France.
Background

ECIL is a joint initiative supported by the European Leukaemia Network, the Infectious Diseases Working Party of the European Association for Blood and Marrow Transplantation (IDWP-EBMT), the Infectious Disease Group of European Organization for Research
and Treatment of Cancer, and the Immunocompromised Host Society (ICHS). For the 6th edition, the ECIL Board decided to address BKPyV and endorsed a panel of experts to review the paediatric and adult literature and propose guidelines for affected haematology patients. The panel included two members of the ECIL Board (S. C., H. E.) and four European experts on BKPyV [T. D., C. H. R., M. K., H. H. H. (IDWP-EBMT member and current ICHS president elect)]. The ECIL-6 Consensus Conference was attended by 55 participants from 24 countries (18 European countries, 6 non-European countries). The supporting scientific societies contributed to the selection of participants by proposing 10 members each, whereas the ECIL board invited the remaining participants based on their scientific and/or clinical expertise in managing infectious complications in haematology patients.
Literature search
The literature search was performed by S. C. and A. P. using the following terms in PubMed: BK polyomavirus, haemorrhagic cystitis, and haematopoietic peripheral stem cell or bone marrow, or cord blood transplantation. Studies published until 31 August 2015 regarding biology and mechanism of pathogenesis of BKPyV as well as diagnosis, prophylaxis, and therapy of BKPyV-HC were identified, missing papers were added, and all were reviewed by all panel experts. The results of the literature search and a preliminary draft of recommendations for diagnosis, prophylaxis and treatment of BKPyV-HC were presented to the ECIL-6 conference for discussion and approval. The final recommendations were graded according to the ECIL-6 evidence-based medicine grading system, presented in Table 1 . 17 An update of the search was performed on 24 January 2017, but was not found to change the current recommendations. A schematic representation of the BKPyV virion structure is shown in Figure 1 and its genome organization is shown in Figure S1 (available as Supplementary data at JAC Online).
An overview of BKPyV biology, immune response and disease is given in the Supplementary data.
BKPyV-HC pathogenesis, clinical presentation and diagnosis
BKPyV-HC is rare in haematology patients other than those undergoing allogeneic HSCT. BKPyV-HC occurs between 2 and 8 weeks (range 1 week-6 months) after HSCT, typically starting during the peri-engraftment period, and should be distinguished from an early-onset HC (,1 week after HSCT) caused by toxicity of the conditioning regimen such as cyclophosphamide and busulfan, or total body irradiation. [18] [19] [20] [21] In HSCT patients, high-level BKPyVviruria .7 log 10 genome equivalents (gEq)/mL is associated with an increased risk for BKPyV-HC. [22] [23] [24] However, high-level BKPyV viruria is not specific for BKPyV-HC, as .80% of all HSCT patients develop high-level BKPyV viruria, while only 5%-20% develop BKPyV-HC. 4, 21 High-level BKPyV viruria and BKPyV-HC are mainly observed in allogeneic HSCT patients receiving full conditioning and an unrelated human leucocyte antigen mismatched donor. [25] [26] [27] Adenovirus, herpes simplex virus, JC polyomavirus, cytomegalovirus (CMV) and other infectious (bacteria, parasite) and non-infectious aetiologies Review JAC (bleeding disorders with or without low platelet count, primary or metastatic neoplasia, vesical catheter or ureteric stenting) may also cause HC, and must be excluded for appropriate diagnosis and management. 4, [28] [29] [30] The severity of haematuria is commonly described as microscopic (grade 1); macroscopic (grade 2); macroscopic with clots (grade 3); or macroscopic with clots and postrenal failure secondary to urinary tract obstruction (grade 4). 4, 21 Thus, the diagnosis of BKPyV-HC requires the triad of: (i) clinical symptoms/signs of cystitis, such as dysuria and lower abdominal pain; (ii) a haematuria grade 2 or higher; and (iii) the demonstration of BKPyV viruria, with viral loads of .7 log 10 copies/mL (Table 2) . Plasma viral loads of .3-4 log 10 copies/mL are seen in more than two-thirds of allogeneic HSCT recipients with BKPyV-HC 1, 10, [31] [32] [33] and declining plasma loads have been found to correlate with clinical recovery. The pathogenesis of BKPyV-HC is not well understood as similarly high urine BKPyV loads are found in kidney transplant patients, most of whom do not develop cystitis or macro-haematuria. 34, 35 Rather, a sequence of events has been suggested, starting with subclinical urothelial damage by the conditioning regimen, high-level BKPyV replication leading to viral denudation of the pre-damaged, regeneration-impaired urothelial lining and urinary leakage in submucosa followed by haemorrhagic exacerbation with abundant inflammatory cell infiltrates following allogeneic stem cell engraftment. 4, 21, 36 Indeed, conditioning involving cyclophosphamide, busulfan and total body irradiation has been implicated in different studies, 25, 26, 29 and the pronounced toxic, inflammatory properties of cyclophosphamide and its metabolite acrolein are supported by clinical and experimental studies. [37] [38] [39] Following the widespread use of hyperhydration, the exposure of the bladder urothelium to toxic metabolites can be reduced, and acute toxicity with early-onset HC has become rare. 4, 21 Nevertheless, subclinical urotoxic exposure may still cause damage with rarefication of the urothelial cell layer, which combined with local inflammation stimulates BKPyV replication during impaired antiviral immune control from cytotoxic T cells. Postengraftment, invading donor immune cells may cause further tissue damage (immune reconstitution inflammatory syndrome). 4 BKPyV-HC generally resolves after 3-5 weeks, but causes significant morbidity, prolonged hospital care with extensive nursing requirements and increases healthcare costs. 3 Moreover, bleeding may be life-threatening requiring urologic interventions including cystectomy and additional complications contributing to, e.g. renal failure may result in fatal outcome. Identifying patients at risk could therefore be an important step for preventing or pre-emptively intervening in the development of BKPyV-HC. 4 
Epidemiology and risk factors for BKPyV-HC
The observed incidence of BKPyV-HC is 8%-25% and 7%-54% in paediatric and adult patients, respectively, being higher after allogeneic than after autologous HSCT and particularly after haploidentical HSCT with post-transplant exposure to cyclophosphamide as prophylaxis for graft versus host disease (GVHD) ( Table 3) . 1, 3, 23, 25, 33, [40] [41] [42] [43] [44] [45] [46] [47] [48] The lower incidence in autologous HSCT may reflect the role of immunosuppression and GVHD in allogeneic HSCT for BKPyV-HC pathogenesis.
5 Table 4 shows the main risk factors of BKPyV-HC. High-level BKPyV viruria and viraemia have both been reported as predictive factors for BKPyV-HC in patients receiving allogeneic HSCT. 1, 3, 8, 9, 23, 25, 30, 33, 40, 41, 49 In a paediatric study a urine BKPyV load of .10 7 gEq/mL had a sensitivity of 86% and specificity of 60%, while a blood BKPyV load of .10 3 gEq/mL had a sensitivity of 100% and a specificity of 86% for HC, respectively. 
Review
BKPyV IgG levels have been low or undetectable in paediatric HSCT patients with BKPyV-HC, 10 but the current data do not permit the use of BKPyV antibody titres to predict risk of BKPyV-HC. Single studies have reported CMV or human herpesvirus (HHV)-6 viraemia as independent risk factors for BKPyV-HC. 30, 33 Furthermore, the stem cell source affects the risk of BKPyV-HC. Patients receiving cord blood units and peripheral blood stem cells have a higher risk of developing BKPyV-HC compared with patients receiving bone marrow grafts. 3, 45 Unrelated donors and GVHD have been associated with BKPyV-HC in line with the notion that the altered allogeneic immune control contributes to pathogenesis. 25, 50 Unrelated donors are associated with a higher cumulative incidence compared with mismatched or matched related donors 25 as well as acute GVHD grade II-IV alone or combined with high-level BKPyV viruria. 9, 23, 49 The intensity of the conditioning regimen was also found to have an impact. Myeloablative conditioning resulted in a higher risk compared with reduced intensity conditioning, with agents such as cyclophosphamide, high-dose busulfan and antithymocyte globulin being independent risk factors. 9, 25, 43, 44 Notably, the age of the HSCT recipient was evaluated and patients .7 years of age had a greater risk for BKPyV-HC than younger children.
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Prophylaxis for BKPyV-HC
The prevention of HC including BKPyV-HC, has been explored using non-specific measures such as hyperhydration and bladder irrigation (Table 5) . In a prospective, randomized study comparing hyperhydration plus forced diuresis with standard hydration plus mesna during the conditioning regimen, the incidence of HC was Allo-HSCT; allogeneic HSCT; Haplo-HSCT: haploidentical HSCT; auto-HSCT, autologous HSCT. In a recent prospective study, bladder irrigation through a threeway Foley catheter did not result in an overall reduction of HC compared with a historical control group, although the mean duration of HC and of hospitalization was reduced. 51 The main drawbacks of these interventions are the risk of fluid overload for hyperhydration and the invasiveness of three-way Foley positioning. Supported by in vitro data demonstrating inhibition of BKPyV replication, 52 ,53 ciprofloxacin has been evaluated for preventing BKPyV-HC in two retrospective and one prospective cohort study with a total of 294 patients (155 treated with ciprofloxacin versus 149 not treated with ciprofloxacin). [54] [55] [56] The results were inconclusive as one study showed only a reduction of BKPyV reactivation, but no difference regarding BKPyV-HC, 54 while the second study reported a reduction of HC, 55 and the third study observed no impact on clinically significant HC. 56 Of note, a randomized, doubleblind, placebo-controlled study on 154 kidney transplant patients showed that 3 month prophylaxis with levofloxacin failed to reduce BKPyV viruria or viraemia significantly, but was associated with increased fluoroquinolone-resistant bacterial infections and an increased rate of tendinitis. 57 
Therapy of BKPyV-HC
Cidofovir treatment of BKPyV-HC has been evaluated in 12 retrospective and 2 prospective studies with a total of 210 patients (Table 6 ). Cidofovir is a nucleotide analogue that inhibits a broad range of DNA viruses, and its active metabolite has a long half-life of 15-65 h that allows administration at weekly intervals. The major drawback is tubular and ocular nephrotoxicity that can be reduced by saline hydration and by probenecid, which inhibits cidofovir uptake into renal tubular epithelial cells. Although there is no agreement regarding dose, modality or frequency of administration, most authors used intravenous cidofovir 3-5 mg/kg/week or bi-weekly together with probenecid to prevent nephrotoxicity. In the absence of probenecid, cidofovir has been administered at a 3-5-fold reduced dose. 58 Disregarding the study heterogeneities, a complete clinical response was reported in 74% of patients, and at least 1 log 10 decline in urine viral loads in 38% and in blood viral loads in 84% of patients (Table 6 ). Mild to moderate increases in serum creatinine concentration were seen in 18% of the patients. 5, 9, 10, 29, 32, 59 In four retrospective studies, 52 patients were treated with low-dose cidofovir at 0.5-1.5 mg/kg/week without probenecid, and a complete clinical response was observed in 83% of patients, a virological response in urine in 62% and in blood in 67% of cases. Also in this group of patients, a mild to moderate increase in serum creatinine concentration was reported in 20% of patients. [60] [61] [62] [63] To overcome the risk of nephrotoxicity, intravesical administration of cidofovir at the dose of 5 mg/kg/week has been reported for 14 patients showing a complete clinical response in 43% of patients and a virological response in 50%. 10, 32, 64, 65 The use of leflunomide, an antimetabolite drug with immunomodulatory and antiviral activity, has been reported in two retrospective studies on 19 patients obtaining an overall complete and partial response rate of 63% and 26%, respectively. 66, 67 Finally, complete clinical response with partial or complete virological response has been reported for two patients treated with vidarabine and one case treated with oral levofloxacin. [68] [69] [70] None of these studies provided a comparison with a control group to estimate a benefit over a spontaneous course and BKPyV-HC clearance.
Other treatments of BKPyV-HC aim at repair and regeneration of the urothelial mucosa through hyperbaric oxygen therapy or by topical application of fibrin glue (Table S1 ). Hyperbaric oxygen therapy was given to a total of 29 patients in different case reports or case series, with a complete clinical response rate of 86% and reduced urine BKPyV load in 65% of patients. [71] [72] [73] [74] [75] The main drawback of hyperbaric oxygen is its limited availability on a larger scale, the requirements for dedicated hyperbaric room facilities, the risk of ear barotrauma/pressure intolerance and claustrophobia linked to the procedure. Finally, topical applications to the damaged bladder mucosa to achieve haemostasis through cystoscopy have been reported in single-centre retrospective series of 35 patients. The complete response rate was 83%. 76 Similarly, several compounds to reduce bleeding have been used in case studies and small series, e.g. FXIII concentrate, 77 intravesical sodium hyaluronate, 78 No adverse effects; beware fluid retention.
No adverse effects; beware, invasive procedure.
Review response rates between 50% and 100%. Brincidofovir, a lipid conjugate of cidofovir, showed in vitro, on primary human urothelial cultures, a potent and long-lasting inhibitory effect on BKPyV replication, 83, 84 but no data are available on the clinical use for BKPyV-HC 83 except a single case of BKPyV nephropathy after an allogeneic HSCT. 85 It is conceivable that brincidofovir might be used in the future for symptomatic HC considering the absence of alternative antiviral compounds with a better safety and tolerability profile.
The reduction of immunosuppression has been used successfully in kidney transplant patients to prevent and/or treat BKPyVassociated nephropathy, 86, 87 but there is no evidence that it has a favourable risk/benefit ratio in HSCT patients due to the risk of worsening the donor versus host alloreactivity and the severity of GVHD. Unlike for BKPyV-associated nephropathy, there is no documented benefit in using intravenous immunoglobulin preparations for BKPyV-HC (see Table 7 ).
Cellular therapy for BKPyV-HC
Owing to the lack of an effective, clinically validated antiviral drug for the treatment of BKPyV-HC, cell therapy approaches have been explored. To induce tissue repair and immune modulatory and anti-inflammatory properties, third party mesenchymal stroma cells were infused into seven patients with BKPyV-HC. 88 In five patients, haematuria resolved with few side effects. Subsequently, a prothrombotic effect of mesenchymal stroma cells was reported 89 thus questioning this type of approach. To target BKPyV replication directly, adoptive transfer of virus-specific T cells was reported using PBMCs from 48 stem cell donors for in vitro stimulation using pools of overlapping peptide libraries covering 12 different immunogenic proteins from five different viruses, i.e. CMV, Epstein-Barr virus, adenovirus, HHV-6 and BKPyV. BKPyV-specific T cell responses were detected in 28 of the cell lines. 
Conclusions and recommendations
BKPyV-HC remains a challenging complication after allogeneic HSCT with average rates of 13%. A BKPyV-HC diagnosis requires the clinical and laboratory triad of cystitis, macrohaematuria and high urine BKPyV loads .7 log 10 gEq/mL (AII h u), but a significant role of other aetiologies must be excluded. Plasma BKPyV loads .1000 gEq/mL has a role for management and follow-up of triadpositive allogeneic HSCT recipients (BII h u). Screening of asymptomatic HSCT patients at risk remains an area of investigation and is presently not recommended, as pre-emptive therapy is not established (DII).
BKPyV-HC prophylaxis relies on hyperhydration (BII t) and bladder irrigation (CII t) aiming at reducing urothelial damage, particularly when using myeloablative conditioning based on cyclophosphamide, busulfan and total body irradiation. Specific antiviral prophylaxis is not available and fluoroquinolones are not recommended given the lack of significant effects on BKPyV replication and HC severity, and the selection of antibiotic resistance (DII h t).
BKPyV-HC treatment is based on the best supportive therapy, such as hyperhydration, bladder irrigation, platelet transfusions as needed to reduce bleeding, and pain treatment (AIII). The risk/ benefit ratio of reduction of immunosuppression is not clear in BKPyV-HC and must be balanced with the risk of worsening or triggering acute GVHD. Antiviral treatment with intravenous cidofovir is controversial due to the absence of randomized controlled studies. Until the availability of safe and effective antivirals, the use of cidofovir may be an option although there is uncertainty of efficacy, the best dose schedule and the need to balance any benefit against its renal side effects (CII u). Non-specific measures aimed at speeding the healing process of the damaged urothelial lining such as hyperbaric oxygen therapy or urologic fibrin glue application have been successful in a limited number of uncontrolled studies (CIII). No recommendation is possible for several other treatments such as the administration of intravesical sodium hyaluronate, intravenous (Table 7) . These evidence-based recommendations are applicable for both paediatric and adult patients.
In conclusion, despite much progress in understanding the pathogenesis, epidemiology and risk factors of BKPyV-HC, this complication still represents a disabling unmet clinical need with limited prophylactic and therapeutic options. To overcome this deficiency will require novel antiviral treatment approaches supported by proper clinical trials.
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